Feed

01/02/2023
CMS ad­vises Cité Ges­tion SA, through­out its ac­quis­i­tion of Sartus Cap­it­al...
In­de­pend­ent private bank Cité Ges­tion SA ("Cité Ges­tion") merged with multi-fam­ily of­fice Sartus Cap­it­al (Genève) SA ("Sartus Cap­it­al") ex­pend­ing its total as­set un­der man­age­ment around CHF 7 bil­lion.The CMS Switzer­land team led by Geneva part­ners Vaïk Müller (co-head of Bank­ing/Fin­ance) and Pas­cal Favre (Head of Cor­por­ate/M&A) ad­vised Cité Ges­tion on M&A and con­trac­tu­al as­pects of the un­der­ly­ing in­vest­ment trans­ac­tions.Geneva-based Sartus Cap­it­al was foun­ded in 2016 and ac­quired by its man­age­ment in 2021. Cité Ges­tion was foun­ded in 2009 as an in­de­pend­ent as­set man­ager be­fore be­ing au­thor­ized as a bank by the Swiss Fin­an­cial Mar­ket Su­per­vis­ory Au­thor­ity FINMA in 2022. Fol­low­ing this mer­ger, Cité Ges­tion’s total as­sets un­der man­age­ment will reach around CHF 7 bil­lion. The com­bined en­tity em­ploys about 100 people at in Geneva, Lausanne, Zurich, and Lugano.
30/01/2023
CMS ad­vised Vista Au­gen­prax­is & Klinik­en on the ac­quis­i­tion of Au­gen­zen­trum...
Vista Klinik Hold­ing AG, dom­i­ciled in Bin­nin­gen (Switzer­land), in­teg­rated Au­gen­zen­trum Thun AG in­to its net­work on 11 Janu­ary 2023 and is now present in the re­gion of Bernese Ober­land. Au­gen­zen­trum Thun, which was foun­ded in 2012, spe­cial­ises in am­bu­lat­ory eye sur­gery and of­fers af­fil­i­ated doc­tors the op­por­tun­ity to provide their pa­tients with first-class care in a pro­fes­sion­al en­vir­on­ment. It is con­sidered the largest oph­thal­mo­logy ser­vice pro­vider in the re­gion.Foun­ded over 30 years ago, Vista Au­gen­prax­en & Klinik­en has be­come a lead­ing centre of ex­cel­lence for oph­thal­mo­logy in Switzer­land. With its nu­mer­ous loc­a­tions, Vista has a broad net­work of eye clin­ics and eye prac­tices. At all sites, spe­cial­ised oph­thal­mo­lo­gists of­fer all treat­ments and sur­gic­al in­ter­ven­tions re­lat­ing to the eye. In this way, Vista guar­an­tees com­pre­hens­ive and lifelong care for its pa­tients. For­ward-look­ing re­search activ­it­ies and the con­tinu­ous train­ing of all em­ploy­ees en­sure qual­ity and sus­tain­ab­il­ity at all sites.A team of CMS Switzer­land, led by Stefan Brunnsch­weiler and Fran­ziska Ham­mer, ad­vised Vista Au­gen­prax­en & Klinik­en on all leg­al mat­ters of the trans­ac­tion.CMS Switzer­land­Stefan Brunnsch­weiler, Part­ner, Cor­por­ate / M&AFran­ziska Ham­mer, Coun­sel, Cor­por­ate / M&A  Anna Mast, As­so­ci­ate, Cor­por­ate / M&ADr Miryam Meile, As­so­ci­ate, Em­ploy­ment­Premton Haziri, At­tor­ney Train­ee
27/01/2023
Quantum com­put­ing pat­ent in­crease is far above av­er­age
On Wed­nes­day 25 Janu­ary 2023, the European Pat­ent Of­fice (EPO) is­sued their In­sight Re­port in­to quantum com­put­ing and pat­ents. In their Re­port, the EPO con­sidered quantum com­put­ing pat­ents in gen­er­al...
26/01/2023
CMS ad­vises Lab14 GmbH on the ac­quis­i­tion of a ma­jor­ity stake in Nanos­urf...
Lab14 GmbH, a port­fo­lio com­pany of RS­BG SE, the in­vest­ment com­pany of the RAG-Found­a­tion, ac­quires a ma­jor­ity stake in Li­estal-based Nanos­urf AG. Zurich, 26 Janu­ary 2023 
26/01/2023
Re­vi­sion of cor­por­ate law
26 Janu­ary 2023On 1 Janu­ary 2023, after a long last­ing polit­ic­al pro­cess, the new cor­por­ate law (amend­ment of the Swiss Code of Ob­lig­a­tions) has come in­to force. In ad­di­tion to cla­ri­fic­a­tions and ad­min­is­trat­ive sim­pli­fic­a­tions, the re­vi­sion of the cor­por­ate law aims, among oth­er things, to make the in­cor­por­a­tion and cap­it­al reg­u­la­tions more flex­ible and to align them with the ac­count­ing law, to mod­ern­ize the pro­vi­sions re­gard­ing the board of dir­ect­ors and the gen­er­al meet­ing of share­hold­ers, and to strengthen share­hold­er rights. In ad­di­tion, the re­vised law ex­pressly al­lows the in­tro­duc­tion of an ar­bit­ra­tion clause in the art­icles of as­so­ci­ation.Be­low you will find an over­view of the most im­port­ant changes.
25/01/2023
CMS Green Globe | New coun­try ad­ded!
Stay in­formed about the latest sus­tain­ab­il­ity claims trends and de­vel­op­ments CMS Green Globe is an in­ter­act­ive plat­form that al­lows busi­nesses and cli­ents to stay aware and duly in­formed about all the main rap­idly chan­ging trends and de­vel­op­ments re­lated to sus­tain­ab­il­ity claims across the world.Here you will find in­form­a­tion on reg­u­la­tion and de­vel­op­ments you need to know when ad­vert­ising and mar­ket­ing your busi­ness or product by us­ing sus­tain­ab­il­ity claims as well as our key ex­perts to sup­port you in nav­ig­at­ing the world of such claims.CMS Green Globe helps you to avoid gre­en­wash­ing your con­sumer in your jur­is­dic­tion as well as across the globe. Dis­cov­er CMS Green Globe Best ex­plored on desktop
25/01/2023
Key out­comes from COP-15
At the end of 2022, the 15th Con­fer­ence of Parties of the United Na­tions Con­ven­tion on Bio­lo­gic­al Di­versity cul­min­ated in a new Glob­al Biod­iversity Frame­work to 2030. Twenty three tar­gets re­quire broad...
24/01/2023
Pri­cing of Medi­cines in Switzer­land | Three-yearly price re­view: What are...
The Fed­er­al Of­fice of Pub­lic Health (FOPH) re­views the price of every medi­cin­al product that is re­im­bursed un­der the stat­utory health in­sur­ance in Switzer­land once every three years. These products are...
18/01/2023
In Vitro Dia­gnost­ic Med­ic­al Devices: Tasks and Li­ab­il­it­ies of the Swiss...
For­eign man­u­fac­tur­ers of in vitro dia­gnost­ic devices med­ic­al devices must des­ig­nate an au­thor­ised rep­res­ent­at­ive (CH-REP) to place their products on the Swiss mar­ket. To act on the man­u­fac­turer­'s be­half...
18/01/2023
What is the sig­ni­fic­ance of a clin­ic­al tri­al pro­tocol as pri­or art at the...
The EPO Ap­peal Board has fur­ther re­fined their view on when pri­or art dis­clos­ures of clin­ic­al tri­al pro­to­cols are an is­sue for pat­entab­il­ity of med­ic­al use claims. De­cision T1806/18 In de­cision T1806/18...
17/01/2023
"La so­ciété an­onyme" co-au­thored by Jérôme Lev­rat
We are pleased to an­nounce and con­grat­u­late our Geneva Part­ner, Jérôme Lev­rat, on the re­cent pub­lic­a­tion of his book "La so­ciété an­onyme" ("The lim­ited com­pany"), which he co-au­thored with Xavi­er Ou­levey (Schulthess Mé­di­as Jur­idiques SA, Janu­ary 2023). Ac­cord­ing to the 2018 stat­ist­ics of the Fed­er­al Stat­ist­ics Of­fice, the lim­ited com­pany is the most com­mon form of leg­al en­tity in Switzer­land. It is not spe­cific­ally "tailored" to fit only large or small struc­tures, but is suit­able for both, mul­tina­tion­al cor­por­a­tions as well as SMEs. It is there­fore of con­sid­er­able prac­tic­al im­port­ance.This book aims at provid­ing eco­nom­ic act­ors (en­tre­pren­eurs, in­vestors, board mem­bers, etc.) and prac­ti­tion­ers with a prac­tic­al ap­proach to the law on the lim­ited com­pany. It in­cor­por­ates the new le­gis­la­tion which came in­to force on 1st Janu­ary 2023 and pays par­tic­u­lar at­ten­tion to the some­times com­plex leg­al ac­tions in this area of law.
15/01/2023
CMS ad­vises the own­er fam­ily on the sale of a ma­jor­ity stake in SCHURTER...
The Swiss in­vestor Capvis, which spe­cial­ises in me­di­um-sized in­vest­ments, ac­quires a ma­jor­ity stake in the Lu­cerne-based SCHURTER Group. The found­ing and pre­vi­ous own­er fam­ily con­tin­ues to hold a stake in the com­pany and is rep­res­en­ted on the board of dir­ect­ors by Thomas Schurter.